Many patients with the more severe form of age-related macular degeneration, a type of vision loss, have trouble with the standard treatment—a once-monthly injection into the eye.
Kodiak Sciences believes it can do better with an experimental drug that may require less frequent injections and the company has filed for an IPO to finance a slate of global clinical studies. Palo Alto, CA-based Kodiak set a preliminary $100 million target for its stock offering. The company has applied for a listing on the Nasdaq exchange under the stock symbol “KOD.” (Kodiak is not to be confused with Cambridge, MA-based Codiak BioSciences.)… Read more »
UNDERWRITERS AND PARTNERS